EGFR and lung cancer: Furthermore, we found that an average of 23.65% (95% confidence interval [CI], 0–50%; Fig. 1G) somatic alterations in BM were not detected in primary lung cancer, including approved actionable mutations such as EGFR, molecularly targeted mutations in development such as ERBB4, and common tumor suppressor gene abnormalities such as TP53 and RB1.